Microbial Fermentation Technology Market size is poised to reach USD 63 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of microbial fermentation technology was USD 33 Billion. The reason behind the growth is due to the rising need for vaccines. Microbial fermentation is a potent, adaptable microbiology method used to generate microbial cells or biomass such as proteins and enzymes for vaccine synthesis, and is also considered crucial in the production of mRNA vaccines. Moreover, it is the most prevalent process of vaccine manufacture followed by purification, which takes about 3 weeks. According to the World Health Organization (WHO), in 2021, over 16 billion vaccination shots costing USD 141 billion were distributed across the globe.
The growing need for microbial contract manufacturing services is believed to fuel the market growth. It has led to the development of a wide range of microbial products, microbial biomass, and enzymes, and has enabled many sorts of bulk manufacturing based on microbial fermentation. Besides this, it has led to advancements in bioprocessing which would make the fermentation process more efficient and reliable in the coming years.
Growth Drivers
Additionally, Artificial intelligence is now being utilized to control fermentation operations in real time, and it can analyze past data to forecast future outcomes.
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~6% |
|
Base Year Market Size (2023) |
~ USD 33 Billion |
|
Forecast Year Market Size (2036) |
~ USD 63 Billion |
|
Regional Scope |
|
Application (Antibiotics, Probiotics Supplements, Monoclonal Antibodies, Recombinant Proteins, Biosimilars, Vaccines, Enzymes, Small Molecules)
The antibiotics segment in the microbial fermentation technology market is estimated to gain a robust revenue share of 33% in the coming years owing to the rising consumption of antibiotics as they have had enormous success in improving health outcomes Moreover, it is expected that increasing personal incomes, and health insurance have driven the consumption of antibiotics across the globe. Antibiotics, the most significant category of bioactive chemicals, can be produced using microbiology through the fermentation method, in which the source microbe is cultured in big containers holding a liquid growth medium.
For instance, Penicillin is an antibiotic used to treat infections in the mouth, throat, gums, and respiratory tract, and urine is created by the fermentation process. It is manufactured in a fermenter that is incubated at around 25oC to 26oC for approximately 5 to 7 days at pH 7 to 7.4 and can be mass-produced through the use of deep-tank batch fermentation. The demand for biopharma products is expanding in several nations owing to rising health concerns and advancements in biotechnology are expected to create profitable possibilities during the forecast period. According to estimates, antibiotic usage is expected to rise by more than 150% globally between 2015 and 2030.
Besides this, the recombinant proteins are poised to gain a notable share by the year 2036. Recombinant proteins are proteins that are encoded by recombinant DNA that facilitates gene expression and messenger RNA translation and are proteins that are generated artificially by inserting certain genes into host organisms such as bacteria or yeast.
End-User (Bio-Pharmaceutical Companies, Contract Research Organizations (CROs), CMOs & CDMOs, Academic & Research Institutes)
The biopharmaceutical companies segment in the microbial fermentation technology market is set to garner a notable share shortly on account of the rising need for biopharmaceutical products. Biopharma products such as enzymes, vaccines, antibiotics, and monoclonal antibiotics are in high demand which is expected to create a huge demand for microbial fermentation technology during the projection period. Moreover, biopharmaceuticals are mostly recombinant therapeutic proteins the production of which, employs a variety of procedures including fermentation that are thought to be crucial in their production. Additionally, many biopharmaceutical and biological products rely on (various) cell-type fermentation where microorganisms such as bacteria, yeast, and molds are increasingly being employed to produce biopharmaceuticals such as vaccines, recombinant proteins, antibiotics, and active pharmaceutical ingredients (APIs).
Furthermore, the CMOs & CDMOs are expected to hold a significant share during the forecast timeframe. CMOs and CDMOs are quickly becoming the preferred choice for biotherapeutics as they can produce industrial enzymes through fermentation. For instance, it is estimated that over 25% of biologics are manufactured by CDMOs/CMOs.
Our in-depth analysis of the global microbial fermentation technology market includes the following segments:
|
Application |
|
|
End-User |
|
|
Type |
|
APAC Market Forecast
Microbial fermentation technology market in Asia Pacific is predicted to account for the largest share of 42% by 2036 impelled by the presence of the developed chemical sector. China's chemical industry continues to outperform all others as the country’s chemical sector has been the world's largest in terms of sales. This has led to the development of the fermentation industry in the country. For instance, China has the world's largest fermentation industry, accounting for more than 60% of the global market share for amino acids, vitamins, and other fermentation products. As a result, the role of fermentation has been increased in various industries which has directly boosted the demand for microbial fermentation technology in the region. China's share of global chemical market sales in 2021 increased to more than 42%, up from around 27% in 2011.
North American Market Statistics
The North America microbial fermentation technology market is estimated to be the second largest, during the forecast timeframe led by an increase in contract development organizations. Moreover, these organizations provide a variety of services to pharmaceutical and biotech companies, boosting development and manufacturing productivity while reducing downtime and expenses. Additionally, contract development and manufacturing organizations (CDMOs) provide a variety of pharmaceutical CDMO services and offer process development and cGMP production in cell culture, microbial fermentation, and gene treatments.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?